Abstract
The role of bone marrow (BM)-derived precursor cells in tumor angiogenesis is not known. We demonstrate here that tumor angiogenesis is associated with recruitment of hematopoietic and circulating endothelial precursor cells (CEPs). We used the angiogenic defective, tumor resistant Id-mutant mice to show that transplantation of wild-type BM or vascular endothelial growth factor (VEGF)-mobilized stem cells restore tumor angiogenesis and growth. We detected donor-derived CEPs throughout the neovessels of tumors and Matrigel-plugs in an Id1+/−Id3−/− host, which were associated with VEGF-receptor-1–positive (VEGFR1+) myeloid cells. The angiogenic defect in Id-mutant mice was due to impaired VEGF-driven mobilization of VEGFR2+ CEPs and impaired proliferation and incorporation of VEGFR1+ cells. Although targeting of either VEGFR1 or VEGFR2 alone partially blocks the growth of tumors, inhibition of both VEGFR1 and VEGFR2 was necessary to completely ablate tumor growth. These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth.
Access options
Subscribe to Journal
Get full journal access for 1 year
$209.00
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.






References
- 1
Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339, 58–61 (1989).
- 2
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86, 353–364 (1996).
- 3
Holash, J. D. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284, 1994–1998 (1999).
- 4
Yancopoulos, G.D. et al. Vascular-specific growth factors and blood vessel formation. Nature. 407, 242–248 (2000).
- 5
Rafii, S. Circulating endothelial precursors: Mystery, reality, and promise. J. Clin. Invest. 105, 17–19 (2000).
- 6
Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997).
- 7
Kalka, C.H. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97, 3422–3427 (2000).
- 8
Takahashi, T.C. et al. Ischemia- and cytokine-induced mobilization of bone-marrow–derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434–438 (1999).
- 9
Peichev, M. et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95, 952–958 (2000).
- 10
Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670–677 (1999).
- 11
Norton, J.D., Deed, R.W., Craggs, G. & Sablitzky, F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell. Biol. 8, 58–65 (1998).
- 12
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1369 (1989).
- 13
Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
- 14
Jain, R.K. et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 95, 10820–10825 (1998).
- 15
Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).
- 16
Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
- 17
Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996).
- 18
Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435–439 (1996).
- 19
Fong, G. H., Zhang, L., Bryce, D.M. & Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 126, 3015–3025 (1999).
- 20
Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575–583 (2001).
- 21
Lin, Y., Weisdorf, D.J., Solovey, A. & Hebbel, R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71–77 (2000).
- 22
Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193, 1005–1014 (2001).
- 23
Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209–5218 (1999).
- 24
Coussens, L.M., Tinkle, C.L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone-marrow–derived cells contributes to skin carcinogenesis. Cell. 103, 481–490 (2000).
- 25
Takakura, N. et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199–209 (2000).
- 26
Donovan, M.J. et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127, 4531–4540 (2000).
- 27
Tam, P.P., Parameswaran, M., Kinder, S.J. & Weinberger, R.P. The allocation of epiblast cells to the embryonic heart and other mesodermal lineages: the role of ingression and tissue movement during gastrulation. Development 124, 1631–1642 (1999).
- 28
Shi, Q. et al. Evidence for circulating bone-marrow–derived endothelial cells. Blood. 92, 362–367 (1998).
- 29
Gill, M. et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 88, 167–174 (2001).
Acknowledgements
We thank S. Kerns, S. Gonzalez, M. Besada, J. Knowles and J. Osoria and the Molecular Core facility (MSKCC) for technical assistance; H. Felsenfeld, S. Felsenfeld, O. Medina and J. Otero for discussions and critical reading; J. Doody and F. Liao for VE-Cadherin antibodies and discussions. This study was supported by the NCI CA 08748 (R.B.) NHLBI, R01 HL61849, HL66592 (S.R.), HL67839 (S.R., K.A.H. and D.L.), American Cancer Society-101396 (S.R.), The Leukemia and Lymphoma Society (S.R.), Portuguese Science and Technology Foundation (S.D. and C.C.) and partially by the Doris Duke foundation (D.L.), the Children's Brain Tumor Foundation (D.L.) and Angiogenex (R.B.).
Author information
Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lyden, D., Hattori, K., Dias, S. et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7, 1194–1201 (2001). https://doi.org/10.1038/nm1101-1194
Received:
Accepted:
Issue Date:
Further reading
-
Treatment of atherosclerosis through transplantation of endothelial progenitor cells overexpressing dimethylarginine dimethylaminohydrolase (DDAH) in rabbits
International Journal of Cardiology (2021)
-
To be or not to be: endothelial cell plasticity in development, repair, and disease
Angiogenesis (2021)
-
Vascularization and osteogenesis in ectopically implanted bone tissue-engineered constructs with endothelial and osteogenic differentiated adipose-derived stem cells
World Journal of Stem Cells (2021)
-
Junctional Adhesion Molecule-C Mediates the Recruitment of Embryonic-Endothelial Progenitor Cells to the Perivascular Niche during Tumor Angiogenesis
International Journal of Molecular Sciences (2020)
-
Evaluating the levels of D-dimer as a primary marker in oral cancers using immunoturbidimetric assay: The original research
International Journal of Molecular & Immuno Oncology (2020)